Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | COMT | P21964 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6988187 | 0.89 | POLB (0.49) | HSP90AA1POLB | |
| SCHEMBL20570323 | 0.81 | KCNH2 (0.49) | HSP90AA1 | |
| SCHEMBL5751594 | 0.80 | LTA4H (0.58) | MGLL | |
| SCHEMBL5811783 | 0.79 | TLR8 (0.49) | POLB | |
| SCHEMBL2872636 | 0.79 | HSP90AA1 (0.60) | HSP90AA1 | |
| SCHEMBL5753419 | 0.79 | PPARA (0.39) | — | |
| SCHEMBL5291581 | 0.78 | TLR8 (0.48) | POLB | |
| SCHEMBL5305301 | 0.78 | TLR8 (0.48) | POLB | |
| SCHEMBL5298962 | 0.78 | HSD11B1 (0.49) | POLB | |
| SCHEMBL22265206 | 0.78 | TLR8 (0.48) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148214-B1 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-12 | — | — | US | disclosed |
| US-7087595-B2 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-08 | — | — | US | disclosed |
| EP-1144411-B1 | ANTIHISTAMINIC SPIRO COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2005-04-27 | — | — | EP | disclosed |
| US-20050026901-A1 | Antiallergens; vision disorders | JANSSENS FRANS EDUARD (BE) | 2005-02-03 | — | — | US | disclosed |
| EP-1144411-A1 | ANTIHISTAMINIC SPIRO COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000037470-A1 | ANTIHISTAMINIC SPIRO COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026901-A1 | Antiallergens; vision disorders | UACA, LTB4R, HLA-B | HSP90AA1 3326/4885POLB 2623/4885KLKB1 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.